Biogen Inc. (BIIB) filed an 8-K on April 29, 2026, announcing its financial results for the first quarter of 2026, which ended on March 31, 2026. The filing includes a press release (Exhibit 99.
BioMarin Pharmaceutical Inc. announced the completion of its acquisition of Amicus Therapeutics, Inc. The merger was finalized on April 27, 2026, with Amicus becoming a wholly-owned subsidiary of BioM...
Perrigo Company plc announced a change to its reporting segments, shifting from a geographic structure to a product category-based structure, effective Q1 2026.
Ionis Pharmaceuticals announced positive topline results from its pivotal Phase 1-3 study of zilganersen for Alexander disease (AxD), a rare and often fatal neurological condition.
Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase. The company announced a 3.
BeOne Medicines Ltd. (BGNE) filed an 8-K on April 14, 2026, pertaining to its 2025 Annual Report filed with the Shanghai Stock Exchange's STAR Market.
Johnson & Johnson's 8-K filing on April 14, 2026, reveals their Q1 2026 financial results and a significant dividend increase.
AbbVie announced an update to its 2026 earnings guidance in an 8-K filing on April 3, 2026. The update reflects a $744 million pre-tax charge for acquired IPR&D (In-Process Research and Development) a...
Biogen Inc. announced it has entered into a definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash, plus one contingent value right (CVR) potentially worth up to $4...
Incyte Corporation announced executive leadership title changes effective March 25, 2026. Pablo J. Cagnoni is now President, Incyte and Global Head of Research and Development, replacing William J.